NCT00780416View on ClinicalTrials.gov

Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C

PHASE3CompletedINTERVENTIONAL
Enrollment

189

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Hepatitis C
Interventions
DRUG

MP-424

750 mg every 8 hours for 12 weeks

DRUG

Ribavirin

600 - 1000 mg/day based on body weight for 24 weeks

DRUG

Peginterferon Alfa-2b

1.5 mcg/kg/week for 24 weeks

DRUG

Ribavirin

600 - 1000 mg/day based on body weight for 48 weeks

DRUG

Peginterferon Alfa-2b

1.5 mcg/kg/week for 48 weeks

Trial Locations (1)

Unknown

Toranomon Hospital, Kawasaki

Sponsors
All Listed Sponsors
collaborator

Vertex Pharmaceuticals Incorporated

INDUSTRY

lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY